Clinical Context
A typical patient is an adult with acquired thrombotic thrombocytopenic purpura (aTTP) presenting to a hospital or outpatient infusion center after confirmation of ADAMTS13 deficiency and clinical diagnosis. The patient often arrives with thrombocytopenia, microangiopathic hemolytic anemia, and variable neurologic or renal symptoms. Initial management includes plasma exchange and immunosuppression (for example, corticosteroids and rituximab). C9047 (injection, caplacizumab-yhdp, 1 mg) is administered as an antithrombotic biologic to inhibit von Willebrand factor–mediated platelet aggregation; dosing typically begins with an intravenous or subcutaneous loading dose at the time of the first plasma exchange, followed by daily subcutaneous injections. Typical workflow: patient assessment and consent → verification of diagnosis and baseline labs (CBC, hemolysis markers, ADAMTS13) → vascular access and plasma exchange setup → preparation and administration of C9047 by an oncology/hematology-trained RN or infusion pharmacist → monitoring for bleeding, allergic reactions, and platelet response → documentation of lot number, dose, route, site, and associated ICD-10 diagnosis in the medical record. Typical sites of service include inpatient hospital wards, hospital outpatient departments, and ambulatory infusion centers experienced in biologic injections and plasma exchange procedures.
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|
96365 | Intravenous infusion, initial, up to 1 hour | Used when caplacizumab is administered IV as an initial infusion in facility settings prior to plasma exchange |
96372 | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | Used when C9047 is administered subcutaneously as a single injection in the clinic or infusion center
36514 | Insertion of non-tunneled centrally inserted central venous catheter; age 5 years or older | Used when central venous access is required for plasma exchange or repeated biologic administrations
99183 | Physician attendance and supervision for moderate sedation services during a procedure | Employed if moderate sedation is required to facilitate administration or associated procedures
36415 | Collection of venous blood by venipuncture | Performed for baseline and serial laboratory monitoring (CBC, hemolysis markers, ADAMTS13) related to therapy